Analysts Issue Forecasts for Aclarion Q1 Earnings

Aclarion, Inc. (NASDAQ:ACON) – Research analysts at Ascendiant Capital Markets issued their Q1 2027 earnings per share estimates for Aclarion in a research report issued to clients and investors on Thursday, May 28th. Ascendiant Capital Markets analyst L. Ward anticipates that the company will post earnings per share of ($1.51) for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Aclarion’s current full-year earnings is ($4.37) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q2 2027 earnings at ($1.30) EPS, Q3 2027 earnings at ($1.30) EPS, Q4 2027 earnings at ($1.36) EPS and FY2027 earnings at ($5.37) EPS.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.55) by $0.21. Aclarion had a negative return on equity of 54.41% and a negative net margin of 10,320.51%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million.

Other analysts have also recently issued research reports about the company. Weiss Ratings upgraded Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.50.

Aclarion Trading Up 3.9%

NASDAQ:ACON opened at $3.50 on Wednesday. Aclarion has a 12-month low of $2.34 and a 12-month high of $12.03. The stock has a 50-day moving average price of $3.29 and a 200 day moving average price of $4.07. The stock has a market capitalization of $8.62 million, a P/E ratio of -0.39 and a beta of 1.22.

Aclarion announced that its Board of Directors has authorized a share buyback plan on Wednesday, April 22nd that permits the company to buyback $2.50 million in shares. This buyback authorization permits the company to purchase up to 31% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.